C07C 335/20
Being further substituted by nitrogen atoms, not being part of nitro or
Official title: being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
C07C335/20 (Being further substituted by nitrogen atoms, not being part of nitro or) appears on 74 US grants and 54 published applications in this corpus.
Search patents in C07C- Granted patents
- 74
- Published applications
- 54
- Assignees
- 63
- Inventors
- 262
- Latest grant
- 25 Jun 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 2 | 0 |
| 1989 | 4 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 7 | 0 |
| 2001 | 8 | 2 |
| 2002 | 5 | 3 |
| 2003 | 2 | 3 |
| 2004 | 2 | 3 |
| 2005 | 0 | 1 |
| 2006 | 2 | 1 |
| 2007 | 2 | 2 |
| 2008 | 1 | 5 |
| 2009 | 1 | 3 |
| 2010 | 3 | 3 |
| 2011 | 3 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 6 |
| 2014 | 2 | 0 |
| 2015 | 2 | 2 |
| 2016 | 2 | 5 |
| 2017 | 3 | 4 |
| 2018 | 3 | 2 |
| 2019 | 3 | 2 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
| 2024 | 1 | 0 |
| 2025 | 0 | 1 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Myc-Max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith25 Jun 2024US 12,017,975 B2The University of British Columbia
- Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease23 Feb 2021US 10,927,075 B2The Jackson Laboratory
- Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof16 Jul 2019US 10,351,522 B2Board of Regents, The University of Texas System
- Fluorine atom-containing compound and use thereof2 Jul 2019US 10,336,686 B2Nissan Chemical Industries, Ltd.
- Methods and compositions for treatment of cancer and autoimmune disease19 Feb 2019US 10,207,988 B2The Jackson Laboratory
- A strategy for the selective removal of mri contrast agents6 Aug 2026US 2026/0226079 A1Portland State University
- Zwitterionic compounds and uses thereof12 Mar 2026US 2026/0069726 A1University of Saskatchewan
- 1,4-diureas and 1,4-dithioureas and uses thereof31 Jul 2025US 2025/0241890 A1Purdue Research Foundation
- Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith4 May 2023US 2023/0134821 A1The University of British Columbia
- Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith14 Apr 2022US 2022/0112157 A1The University of British Columbia
Most cited
By later US patents
- Cell differentiation inducer110US 6,174,905 B1Mitsui Chemicals, Inc. · 2001
- Fluorescent labels for immunoassay105US 4,637,988 AEastman Kodak Company · 1987
- 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds79US 6,818,634 B2Paratek Pharmaceuticals, Inc. · 2004
- 13-substituted methacycline compounds59US 6,500,812 B2Paratek Pharmaceuticals, Inc. · 2002
- Terpyridine chelating agents58US 4,859,777 AEastman Kodak Company · 1989